Cargando…

Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson’s Syndrome: A Case Report

Nelson’s syndrome is considered a severe side effect that can occur after a total bilateral adrenalectomy in patients with Cushing’s disease. It usually presents with clinical manifestations of an enlarging pituitary tumor including visual and cranial nerve alterations, and if not treated, can cause...

Descripción completa

Detalles Bibliográficos
Autores principales: Mirallas, Oriol, Filippi-Arriaga, Francesca, Hernandez Hernandez, Irene, Aubanell, Anton, Chaachou, Anas, Garcia-Alvarez, Alejandro, Hernando, Jorge, Martínez-Saez, Elena, Biagetti, Betina, Capdevila, Jaume
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632214/
https://www.ncbi.nlm.nih.gov/pubmed/34858324
http://dx.doi.org/10.3389/fendo.2021.731631
_version_ 1784607714008104960
author Mirallas, Oriol
Filippi-Arriaga, Francesca
Hernandez Hernandez, Irene
Aubanell, Anton
Chaachou, Anas
Garcia-Alvarez, Alejandro
Hernando, Jorge
Martínez-Saez, Elena
Biagetti, Betina
Capdevila, Jaume
author_facet Mirallas, Oriol
Filippi-Arriaga, Francesca
Hernandez Hernandez, Irene
Aubanell, Anton
Chaachou, Anas
Garcia-Alvarez, Alejandro
Hernando, Jorge
Martínez-Saez, Elena
Biagetti, Betina
Capdevila, Jaume
author_sort Mirallas, Oriol
collection PubMed
description Nelson’s syndrome is considered a severe side effect that can occur after a total bilateral adrenalectomy in patients with Cushing’s disease. It usually presents with clinical manifestations of an enlarging pituitary tumor including visual and cranial nerve alterations, and if not treated, can cause death through local brain compression or invasion. The first therapeutic option is surgery but in extreme cases of inaccessible or resistant aggressive pituitary tumors; the off-label use of chemotherapy with capecitabine and temozolomide can be considered. However, the use of this treatment is controversial due to adverse events, lack of complete response, and inability to predict results. We present the case of a 48-year-old man diagnosed with Nelson’s syndrome with prolonged partial response and significant clinical benefit to treatment with capecitabine and temozolomide.
format Online
Article
Text
id pubmed-8632214
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86322142021-12-01 Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson’s Syndrome: A Case Report Mirallas, Oriol Filippi-Arriaga, Francesca Hernandez Hernandez, Irene Aubanell, Anton Chaachou, Anas Garcia-Alvarez, Alejandro Hernando, Jorge Martínez-Saez, Elena Biagetti, Betina Capdevila, Jaume Front Endocrinol (Lausanne) Endocrinology Nelson’s syndrome is considered a severe side effect that can occur after a total bilateral adrenalectomy in patients with Cushing’s disease. It usually presents with clinical manifestations of an enlarging pituitary tumor including visual and cranial nerve alterations, and if not treated, can cause death through local brain compression or invasion. The first therapeutic option is surgery but in extreme cases of inaccessible or resistant aggressive pituitary tumors; the off-label use of chemotherapy with capecitabine and temozolomide can be considered. However, the use of this treatment is controversial due to adverse events, lack of complete response, and inability to predict results. We present the case of a 48-year-old man diagnosed with Nelson’s syndrome with prolonged partial response and significant clinical benefit to treatment with capecitabine and temozolomide. Frontiers Media S.A. 2021-11-11 /pmc/articles/PMC8632214/ /pubmed/34858324 http://dx.doi.org/10.3389/fendo.2021.731631 Text en Copyright © 2021 Mirallas, Filippi-Arriaga, Hernandez Hernandez, Aubanell, Chaachou, Garcia-Alvarez, Hernando, Martínez-Saez, Biagetti and Capdevila https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Mirallas, Oriol
Filippi-Arriaga, Francesca
Hernandez Hernandez, Irene
Aubanell, Anton
Chaachou, Anas
Garcia-Alvarez, Alejandro
Hernando, Jorge
Martínez-Saez, Elena
Biagetti, Betina
Capdevila, Jaume
Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson’s Syndrome: A Case Report
title Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson’s Syndrome: A Case Report
title_full Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson’s Syndrome: A Case Report
title_fullStr Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson’s Syndrome: A Case Report
title_full_unstemmed Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson’s Syndrome: A Case Report
title_short Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson’s Syndrome: A Case Report
title_sort aggressive pituitary macroadenoma treated with capecitabine and temozolomide chemotherapy combination in a patient with nelson’s syndrome: a case report
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632214/
https://www.ncbi.nlm.nih.gov/pubmed/34858324
http://dx.doi.org/10.3389/fendo.2021.731631
work_keys_str_mv AT mirallasoriol aggressivepituitarymacroadenomatreatedwithcapecitabineandtemozolomidechemotherapycombinationinapatientwithnelsonssyndromeacasereport
AT filippiarriagafrancesca aggressivepituitarymacroadenomatreatedwithcapecitabineandtemozolomidechemotherapycombinationinapatientwithnelsonssyndromeacasereport
AT hernandezhernandezirene aggressivepituitarymacroadenomatreatedwithcapecitabineandtemozolomidechemotherapycombinationinapatientwithnelsonssyndromeacasereport
AT aubanellanton aggressivepituitarymacroadenomatreatedwithcapecitabineandtemozolomidechemotherapycombinationinapatientwithnelsonssyndromeacasereport
AT chaachouanas aggressivepituitarymacroadenomatreatedwithcapecitabineandtemozolomidechemotherapycombinationinapatientwithnelsonssyndromeacasereport
AT garciaalvarezalejandro aggressivepituitarymacroadenomatreatedwithcapecitabineandtemozolomidechemotherapycombinationinapatientwithnelsonssyndromeacasereport
AT hernandojorge aggressivepituitarymacroadenomatreatedwithcapecitabineandtemozolomidechemotherapycombinationinapatientwithnelsonssyndromeacasereport
AT martinezsaezelena aggressivepituitarymacroadenomatreatedwithcapecitabineandtemozolomidechemotherapycombinationinapatientwithnelsonssyndromeacasereport
AT biagettibetina aggressivepituitarymacroadenomatreatedwithcapecitabineandtemozolomidechemotherapycombinationinapatientwithnelsonssyndromeacasereport
AT capdevilajaume aggressivepituitarymacroadenomatreatedwithcapecitabineandtemozolomidechemotherapycombinationinapatientwithnelsonssyndromeacasereport